Past clinical trials can be found here.
CAMP4 Therapeutics ASO Clinical Trial (Australia) – COMING SOON!
CAMP4 Therapeutics ASO Clinical Trial (Argentina) – COMING SOON!
CAMP4 Therapeutics ASO Clinical Trial (United Kingdom) – COMING SOON!
Institution: CAMP4 Therapeutics
While we wait for details, here are some discussions we’ve shared leading up to the first-ever, disease-modifying trial for SYNGAP1-Related Disorders:
CAMP4 Trial Approved in Australia & Argentina!
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
Getting to an ASO Clinical Trial: CAMP4
Dr. Yuri Maricich, MD MBA
Josh Mandel-Brehm President and CEO, CAMP4 Therapeutics;
Mike Graglia, CEO and Founder, CURE SYNGAP1
The EMERALD Study (At Home, In Clinic, or Combination)
Now Enrolling!
Institution: Praxis Precision Medicines
Description: The EMERALD study is investigating a new potential treatment (Relutrigine) for children and adults with any DEEs, such as SYNGAP1-related disorders. You choose where your child participates in the study – at home, in a clinic, or a combination of the two.
Inclusion Criteria: This study is open to individuals aged 2 through 65 years of age who have a diagnosis of SYNGAP1-related disorders (or another DEE). The individual must have at least 4 motor seizures (seizures that involve movement including atonic [or drop] seizures) in the 4 weeks prior to screening. US, Europe, Australia, South America.
How to sign up: Visit https://www.resiliencestudies.com/emerald and once you have signed up, email CURE SYNGAP1 at studies@cureSYNGAP1.org so we can monitor participation.
DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Now Enrolling!
Institution: Lundbeck
Inclusion Criteria:
- Diagnosis of DEE (this includes SYNGAP1)
- Initial seizure activity experienced between birth to 8 years old -or- LGS diagnosis
- Participants must be 2 years of age or older
There is no cost to participate in this study.
How to sign up: Visit DEEpDEEstudy.com to express interest in this study. Please also contact Corey Baysden & Marta Caceres Dahiya via corey@cureSYNGAP1.org and marta@cureSYNGAP1.org to keep CURE SYNGAP1 apprised of your participation.